JDRF Announces Diabetes Research Program with Johnson & Johnson

This press release is an announcement submitted by JDRF, and was not written by Diabetes Health.

Program Focuses on Discovery and Development of Drugs to Promote Beta Cell Survival and Function in Diabetes

Dec 19, 2009

NEW YORK, Dec. 17, 2009 - The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes.  The program will look to fund research at academic centers around the world that could eventually lead to novel drug targets and industry collaborations for the treatment of type 1 diabetes.

The joint program will solicit grant proposals from academia and medical research foundations for one- or two-year research projects.  The research will focus on agents and compounds that safely promote survival and function of beta cells - the cells within the pancreas that produce insulin, and that are lost in the immune attack that causes type 1 diabetes.  Preserving or maintaining beta cell mass and activity in people with type 1 diabetes can reduce insulin requirements, make controlling the disease easier and more effective, and lower the risk of both short and long-term complications of the disease.

"This program will clearly help accelerate the translation of basic research into therapies useful in the treatment of diabetes," said Alan J. Lewis, Ph.D., President and Chief Executive Officer of JDRF.  "By creating this novel incubator program to support early stage research with a company known for first-class research and significant experience in the commercialization of products, we believe we can increase the number of viable drug targets identified and fundamentally change the pace of diabetes research." 

Funding decisions will be led by a combined review committee consisting of representatives from the JDRF and The Johnson & Johnson Corporate Office of Science and Technology and its affiliates, with oversight from a Scientific Advisory Board and JDRF volunteers.

"Beta cell survival is a critical research focus to advance the understanding of the natural history of diabetes and importantly, where to intervene to slow or arrest the progression of this disease," said Martin Fitchet, M.D, Therapeutic Area Head, Cardiovascular and Metabolism for Johnson & Johnson Pharmaceutical Research and Development, L.L.C.  "Establishing this alliance with The Juvenile Diabetes Research Foundation is a part of our commitment to access external innovation to drive discovery and development of new therapies for the patients who most need them." 

The program aims to contribute to medical research funding in the discovery of better treatments for diabetes, facilitating cooperation between the pharmaceutical industry and universities in with the potential to lead to drug targets and products. 

About JDRF

JDRF is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder and advocate of type 1 research. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Type 1 diabetes is a disease which strikes children and adults suddenly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its eventual and devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.

Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.4 billion to diabetes research, including more than $100 million in FY2009.

For more information, please visit www.jdrf.org 

Click Here To View Or Post Comments

Categories: Beta Cells, Diabetes, Diabetes, Insulin, Research, Type 1 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (2)

You May Also Be Interested In...


Comments

Posted by Anonymous on 21 December 2009

It would be great if J&J would support Dr. Faustman's research. It is very promissing, does not compromise values and would be affordable for patients once research is completed.
Rita Ortiz, Calgary, Canada

Posted by Anonymous on 22 December 2009

Ordinarily I would applaud this new agreement between JDF and Johnson and Johnson to sponsor research into drugs that will protect beta cells. But since the fruit of this research is already in clinical trials at Harvard/Mass. General Hospital under the aegis of Dr. Denise Faustman, I am perplexed. Why bother funding research which will duplicate her work when she's presently seeking funding for Phase II clinical trials?

Since this agreement will duplicate the work Dr. Faustman has already done, they're wasting money and delaying bringing a cure to all of us who suffer from type 1 diabetes. Dr. Faustman is ready to launch the Phase II trials of the drug BCG. All she needs is $25 million dollars. If JDF gave Dr. Faustman that money, she would be ready to publish her CURE for type 1 diabetes in about 12 months. Can the same be said about the results of JDF’s investment with Johnson & Johnson?

Whose side is JDF on, the companies who want to sell drugs or the diabetics who need a cure for this scourge? I can see why Johnson & Johnson wants to find some other drug rather than BCG. They can't make any money from a drug like BCG that is off-patent. But what excuse does JDF have for abandoning Dr. Faustman’s research which is just months away from a cure?

This is why I send my contributions directly to Harvard/Mass. General Hospital rather than the JDF, because I know that the money will be well spent on an imminent cure.


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.